DaVita Files Second Quarter 10-Q as Insider Sales Continue
The kidney care provider submitted its quarterly report to the SEC amid recent divestments by major shareholders including Berkshire Hathaway.
Quarterly Filing Submitted
DaVita Inc. (NYSE: DVA) filed its quarterly report on Form 10-Q with the Securities and Exchange Commission on August 4, according to SEC EDGAR filings. The Denver-based kidney dialysis services provider, with a market capitalization of approximately $15 billion, submitted the standard disclosure document covering its most recent fiscal quarter.
The company's shares closed at $227.99 in their last trading session prior to the filing.
Recent Insider Activity
MarginX data reveals notable insider selling activity at DaVita in recent periods. Berkshire Hathaway Inc., the conglomerate led by Warren Buffett that has been a long-term investor in the dialysis operator, sold 182,980 shares. Additionally, Javier Rodriguez, who serves as CEO of DaVita, conducted two separate transactions, selling 39,407 shares and 30,000 shares respectively.
Insider sales can occur for various reasons including portfolio rebalancing, tax planning, or personal financial needs, and do not necessarily signal concerns about company fundamentals.
Macro Context
The filing comes as healthcare stocks navigate a complex macroeconomic environment. MarginX data indicates two upcoming Federal Reserve policy decisions on the calendar that could influence broader market conditions: the September 16 FOMC meeting will include updated economic projections alongside the rate decision, followed by another policy announcement on October 28.
Interest rate policy remains a key consideration for healthcare services companies like DaVita, which operate with significant capital requirements and debt loads typical of the dialysis industry.
Company Profile
DaVita operates as one of the largest providers of kidney dialysis services in the United States, serving patients with chronic kidney failure and end-stage renal disease. The company's business model depends heavily on reimbursement rates from government programs including Medicare and Medicaid, as well as private insurers.
This article was generated by MarginX from public news on 2026-08-04. It is not investment advice.